NCT03474497 2026-01-29
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Phase 1/2 Active not recruiting
University of California, Davis
M.D. Anderson Cancer Center
University of Southern California
University of Wisconsin, Madison
Providence Health & Services